home / stock / okyo / okyo short
Short Information | OKYO Pharma Limited (NASDAQ:OKYO)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 178,999 |
Total Actual Volume | 652,766 |
Short Trends | |
---|---|
Cover Days | 17 |
Short Days | 2 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 8,950 |
Average Short Percentage | 25.58% |
Is there a OKYO Short Squeeze or Breakout about to happen?
See the OKYO Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-25-2024 | $1.51 | $1.35 | $1.52 | $1.285 | 48,527 | 15,471 | 31.88% |
07-24-2024 | $1.585 | $1.55 | $1.7 | $1.51 | 16,318 | 5,446 | 33.37% |
07-23-2024 | $1.68 | $1.64 | $1.7 | $1.6001 | 13,394 | 5,821 | 43.46% |
07-22-2024 | $1.7 | $1.68 | $1.7 | $1.6006 | 30,018 | 3,334 | 11.11% |
07-19-2024 | $1.64 | $1.66 | $1.74 | $1.57 | 48,851 | 9,029 | 18.48% |
07-18-2024 | $1.5268 | $1.585 | $1.59 | $1.5216 | 9,569 | 2,719 | 28.41% |
07-17-2024 | $1.6 | $1.6 | $1.66 | $1.5001 | 35,176 | 8,151 | 23.17% |
07-16-2024 | $1.59 | $1.565 | $1.6 | $1.5289 | 57,074 | 15,362 | 26.92% |
07-15-2024 | $1.6 | $1.59 | $1.6 | $1.4201 | 30,748 | 8,196 | 26.66% |
07-12-2024 | $1.53 | $1.59 | $1.6 | $1.42 | 65,336 | 17,054 | 26.1% |
07-11-2024 | $1.28 | $1.47 | $1.64 | $1.28 | 242,234 | 74,169 | 30.62% |
07-10-2024 | $1.2 | $1.17 | $1.2 | $1.15 | 15,537 | 1,270 | 8.17% |
07-09-2024 | $1.1782 | $1.19 | $1.19 | $1.1532 | 3,705 | 53 | 1.43% |
07-08-2024 | $1.17 | $1.1999 | $1.2 | $1.17 | 1,969 | 1,036 | 52.62% |
07-05-2024 | $1.19 | $1.2 | $1.2 | $1.1645 | 2,685 | 613 | 22.83% |
07-03-2024 | $1.205 | $1.18 | $1.205 | $1.18 | 487 | 24 | 4.93% |
07-02-2024 | $1.22 | $1.21 | $1.22 | $1.19 | 7,023 | 1,313 | 18.7% |
07-01-2024 | $1.15 | $1.24 | $1.28 | $1.15 | 6,667 | 2,099 | 31.48% |
06-28-2024 | $1.12 | $1.19 | $1.21 | $1.12 | 5,188 | 654 | 12.61% |
06-27-2024 | $1.13 | $1.1308 | $1.155 | $1.11 | 12,260 | 7,185 | 58.61% |
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...